STEMCELL's T-cell reagents licensed by GE Healthcare

GE Healthcare has announced an exclusive licensing agreement with Canada’s STEMCELL Technologies that will see the latter provide its T-cell reagents for commercial-scale cell therapy production. The agreement supports GE’s mission to provide an ecosystem of tools and services to the cell therapy industry.

Under the agreement, GE Healthcare will commercialise cGMP-grade versions of STEMCELL Technologies’ T-cell reagents for the isolation, activation and culture of T cells in clinical applications. Said to be critical tools in the development and manufacturing of cell and gene therapies intended for administration to patients, the following reagents will be qualified and licensed by GE Healthcare:

• ImmunoCult Human CD3/CD28 T Cell Activator
• ImmunoCult Human CD3/CD28/CD2 T Cell Activator
• EasySep Release Human CD3 Positive Selection Kit
• ImmunoCult-XF T Cell Expansion Medium

“As cell therapies move to commercialisation, the need increases for technologies and industrial capabilities that enable efficient, scalable production of these therapies,” said Cindy Collins, GM cell therapy, GE Healthcare. “The availability of cGMP-grade T-cell reagents significantly expands the complete solution that our customers need to bring cell therapies into widespread clinical practice.”

“This partnership with GE will give our customers the confidence of a path to the clinic with a suite of critical cGMP grade T-cell reagents,” added STEMCELL Technologies President and CEO Allen Eaves. “STEMCELL is a recognised leader in cell culture media and cell separation products and GE can leverage our expertise in T-cell isolation, activation and culture to help the industry evolve and make these promising therapies, such as CAR-T cells and TCR-engineered T cells, a clinical reality.”